Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMMAC MDMA-assisted therapy for depression and anxiety in advanced-stage cancer
ACTRN12619001334190Phase 2Recruiting
- Sponsor
- University of Otago
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of midomafetamine in major depressive disorder (MDD), anxiety disorder, adjustment disorder (AD) and 1 more (2 arms), sponsored by University of Otago. Primary endpoint: Change from baseline in Montgomery Asberg Depression Rating Scale score. Started Jul 2023; status: recruiting.
02
Drugs
midomafetamine
03
Conditions
major depressive disorder (MDD)anxiety disorderadjustment disorder (AD)cancer
Beyond the preview
Go deeper on ACTRN12619001334190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001334190.